Clinical Policy: (Opsumit) Reference Number: ERX.SPMN.88 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Policy/Criteria It is the policy of health plans affiliated with Envolve Pharmacy Solutions that macitentan (Opsumit ) is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Pulmonary Arterial Hypertension (PAH) (must meet all): 1. Prescribed by or in consultation with a cardiologist or pulmonologist experienced in the diagnosis and treatment of pulmonary hypertension; 2. Age 18 years; 3. Diagnosis of PAH WHO Group 1 (appendix B) confirmed by right heart catheterization and with one of the following: a. Inadequate response or contraindication to acute vasodilator testing; or b. Trial and failure of, or contraindication to, calcium channel blockers; 4. WHO/NYHA functional class II, III, or IV (appendix C); 5. Prescribed dose of Opsumit does not exceed 10 mg once daily. Approval Duration: 3 months B. Other diagnoses/indications: Refer to ERX.SPMN.16 - Global Biopharm Policy. II. Continued Approval A. Pulmonary Arterial Hypertension (PAH) (must meet all): 1. Currently receiving medication via health plan benefit or member has previously met all initial approval criteria. Approval Duration: 6 months B. Other diagnoses/indications (must meet 1 or 2): 1. Currently receiving medication via health plan benefit and documentation supports positive response to therapy; or 2. Refer to ERX.SPMN.16 - Global Biopharm Policy. Page 1 of 5
Background Description/Mechanism of Action: Opsumit (macitentan) is an endothelin receptor antagonist (ERA). Endothelin (ET-1) and its receptors (ETA and ETB) mediate a variety of deleterious effects, such as vasoconstriction, fibrosis, proliferation, hypertrophy, and inflammation. In disease conditions such as PAH, the local ET system is upregulated and is involved in vascular hypertrophy and in organ damage. is an ERA that prevents the binding of ET-1 to both ETA and ETB receptors. displays high affinity and sustained occupancy of the ET receptors in human pulmonary arterial smooth muscle cells. One of the metabolites of macitentan is also pharmacologically active at the ET receptors and is estimated to be about 20% as potent as the parent drug in vitro. FDA Approved Indication: Opsumit (macitentan) is an ERA/oral tablet formulation indicated for: Treatment of PAH (WHO Group I) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Opsumit also reduced hospitalization for PAH. Effectiveness was established in a long-term study in PAH patients with predominantly WHO Functional Class II-III symptoms treated for an average of 2 years. Patients were treated with OPSUMIT monotherapy or in combination with phosphodiesterase-5 inhibitors or inhaled prostanoids. Patients had idiopathic and heritable PAH (57%), PAH caused by connective tissue disorders (31%), and PAH caused by congenital heart disease with repaired shunts (8%). Appendices Appendix A: Abbreviation Key CCB: calcium channel blocker CTEPH: chronic thromboembolic pulmonary hypertension ETRA: endothelin receptor antagonist FC: functional classification IP receptor agonist: prostacyclin receptor agonist NYHA: New York Heart Association PAH: pulmonary arterial hypertension PDE5 inhibitor: phosphodiesterase-5 inhibitor PH: pulmonary hypertension PVOD: pulmonary veno-occlusive disease sgc stimulator: soluble guanylate cyclase stimulator WHO: World Health Organization Appendix B: WHO Classification of Pulmonary Hypertension (PH) Group 1 PAH (pulmonary arterial hypertension) Group 2 PH (left heart disease) Group 3 PH (lung disease) Group 4 PH (chronic thromboembolic pulmonary hypertension - CTEPH) Group 5 PH (multifactorial) Page 2 of 5
Appendix C: Advanced Therapies for PAH WHO Group 1 in Adults by WHO/NYHA Functional Classification: FC I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope. o No advanced therapy indicated. FC II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope. o Indicated advanced therapies: ETRAs, PDE5 inhibitors, and/or sgc stimulators*. FC III: Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. o Indicated advanced therapies: as in FC II with the addition of a parenteral or inhaled prostanoid if presence of progression and/or markers of poor clinical prognosis despite treatment with one or two classes of oral agents. FC IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by any physical activity. o Indicated advanced therapies: prostanoids, ETRAs, PDE5 inhibitors, and/or sgc stimulators*. *Combinations to avoid: PDE5 inhibitors with sgc stimulators due to hypotension Advanced Therapies Prostanoids: epoprostenol* (generic*, Flolan*, Veletri*); treprostinil (Orenitram**, Remodulin*, Tyvasco+); iloprost (Ventavis+) PDE5 inhibitors: sildenafil (Revatio**); tadalafil (Adcirca**) ETRAs: ambrisentan (Letairis**); bosentan (Tracleer**); macitentan (Opsumit**) sgc stimulators: riociguat (Adempas**) IP receptor agonists: selexipag (Uptravi**) Formulations: *injection; **oral tablet; +inhalation solution Reviews, Revisions, and Approvals Date Approval Date Policy created. 05/16 06/16 Page 3 of 5
References 1. Opsumit Prescribing Information. South San Francisco, CA: Actelion Pharmaceuticals, Inc.; December 2015. 2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association - developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009; 53(17): 1573-1619. 3. Taichman D, Ornelas J, Chung L, et. al. CHEST guideline and expert panel report: pharmacologic therapy for pulmonary arterial hypertension in adults, Chest. 2014; 146 (2): 449-475. 4. Rubin LJ and Hopkins W. Overview of pulmonary hypertension in adults. In: UpToDate, Waltham, MA: Walters Kluwer Health; 2016. Available at UpToDate.com. Accessed February 23, 2016. 5. Rubin LJ and Hopkins W. Clinical features and diagnosis of pulmonary hypertension in adults. In: UpToDate, Waltham, MA: Walters Kluwer Health; 2016. Available at 6. Hopkins W and Rubin LJ. Treatment of pulmonary hypertension in adults. In: UpToDate, Waltham, MA: Walters Kluwer Health; 2016. Available at UpToDate.com. Accessed February 23, 2016. 7. Kim NH, Delcroix M, Jenkins DP, et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013; 62(25): Suppl D92-99. 8. Fedullo PF. Clnical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension. In: UpToDate, Waltham, MA: Walters Kluwer Health; 2016. Available at 9. Fedullo PF. Overview of the treatment of chronic thromboembolic pulmonary hypertension. In: UpToDate, Waltham, MA: Walters Kluwer Health; 2016. Available at 10. Fedullo PF. Chronic thromboembolic pulmonary hypertension: Surgical treatment. In: UpToDate, Waltham, MA: Walters Kluwer Health; 2016. Available at UpToDate.com. Accessed February 23, 2016. 11. Fedullo PF. Chronic thromboembolic pulmonary hypertension: Medical treatment. In: UpToDate, Waltham, MA: Walters Kluwer Health; 2016. Available at UpToDate.com. Accessed February 23, 2016. 12. Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015 Nov 24; 132(21): 2037-99. DOI: 10.1161/CIR.0000000000000329. Available at http://circ.ahajournals.org. Page 4 of 5
Important Reminder This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions. 2016 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein. Page 5 of 5